262 related articles for article (PubMed ID: 26516441)
1. Impact of hyponatremia on frequency of complications in patients with decompensated liver cirrhosis.
Barakat AA; Metwaly AA; Nasr FM; El-Ghannam M; El-Talkawy MD; Taleb HA
Electron Physician; 2015 Oct; 7(6):1349-58. PubMed ID: 26516441
[TBL] [Abstract][Full Text] [Related]
2. Hyponatremia in cirrhosis and end-stage liver disease: treatment with the vasopressin V₂-receptor antagonist tolvaptan.
Gaglio P; Marfo K; Chiodo J
Dig Dis Sci; 2012 Nov; 57(11):2774-85. PubMed ID: 22732834
[TBL] [Abstract][Full Text] [Related]
3. The association between the serum sodium level and the severity of complications in liver cirrhosis.
Kim JH; Lee JS; Lee SH; Bae WK; Kim NH; Kim KA; Moon YS
Korean J Intern Med; 2009 Jun; 24(2):106-12. PubMed ID: 19543488
[TBL] [Abstract][Full Text] [Related]
4. Frequency of hyponatraemia and its influence on liver cirrhosis-related complications.
Shaikh S; Mal G; Khalid S; Baloch GH; Akbar Y
J Pak Med Assoc; 2010 Feb; 60(2):116-20. PubMed ID: 20209698
[TBL] [Abstract][Full Text] [Related]
5. Systemic vascular resistance and fluid status in patients with decompensated liver cirrhosis with or without functional renal failure in Egypt.
Barakat AA; Nasr FM; Metwaly AA; El-Ghannam M
Electron Physician; 2015 Aug; 7(4):1174-82. PubMed ID: 26396731
[TBL] [Abstract][Full Text] [Related]
6. Vasopressin V2-receptor antagonists in patients with cirrhosis, ascites and hyponatremia.
Habib S; Boyer TD
Therap Adv Gastroenterol; 2012 May; 5(3):189-97. PubMed ID: 22570679
[TBL] [Abstract][Full Text] [Related]
7. Clinical Implications, Evaluation, and Management of Hyponatremia in Cirrhosis.
Praharaj DL; Anand AC
J Clin Exp Hepatol; 2022; 12(2):575-594. PubMed ID: 35535075
[TBL] [Abstract][Full Text] [Related]
8. Complications of cirrhosis. II. Renal and circulatory dysfunction. Lights and shadows in an important clinical problem.
Arroyo V; Jiménez W
J Hepatol; 2000; 32(1 Suppl):157-70. PubMed ID: 10728802
[TBL] [Abstract][Full Text] [Related]
9. [Serum sodium concentration profile for cirrhotic patients and its effect on the prognostic value of the MELD score].
Zhang JY; Qin CY; Jia JD; Wang BE
Zhonghua Gan Zang Bing Za Zhi; 2012 Feb; 20(2):108-11. PubMed ID: 22464781
[TBL] [Abstract][Full Text] [Related]
10. Hyponatremia in cirrhosis: Risk factors and prognostic value.
Ennaifer R; Cheikh M; Romdhane H; El Elj R; Ben Nejma H; Bougassas W; Bel Hadj N
Tunis Med; 2016 May; 94(5):401-405. PubMed ID: 27801493
[TBL] [Abstract][Full Text] [Related]
11. Association between the Serum Sodium Levels and the Response to Tolvaptan in Liver Cirrhosis Patients with Ascites and Hyponatremia.
Hayashi M; Abe K; Fujita M; Okai K; Takahashi A; Ohira H
Intern Med; 2018 Sep; 57(17):2451-2458. PubMed ID: 29607963
[TBL] [Abstract][Full Text] [Related]
12. Hyponatremia and Its Correlation With Hepatic Encephalopathy and Severity of Liver Disease.
Younas A; Riaz J; Chughtai T; Maqsood H; Saim M; Qazi S; Younus S; Ghaffar U; Khaliq M
Cureus; 2021 Feb; 13(2):e13175. PubMed ID: 33717720
[TBL] [Abstract][Full Text] [Related]
13. [Refractory ascites and dilutional hyponatremia: current management and new aquaretics].
Torre Delgadillo A
Rev Gastroenterol Mex; 2005; 70(3):299-311. PubMed ID: 17063787
[TBL] [Abstract][Full Text] [Related]
14. [Treatment of ascites, hyponatremia and hepatorenal syndrome in liver cirrhosis].
Ackermann D
Ther Umsch; 2009 Nov; 66(11):747-51. PubMed ID: 19885792
[TBL] [Abstract][Full Text] [Related]
15. Hyponatremia in cirrhosis.
Sigal SH
J Hosp Med; 2012 Apr; 7 Suppl 4():S14-7. PubMed ID: 22489081
[TBL] [Abstract][Full Text] [Related]
16. Systemic vascular resistance in cirrhosis: a predictor of severity?
Gaduputi V; Abdulsamad M; Sakam S; Abbas N; Tariq H; Ihimoyan A
Hepat Med; 2014; 6():95-101. PubMed ID: 25187743
[TBL] [Abstract][Full Text] [Related]
17. Persistent ascites and low serum sodium identify patients with cirrhosis and low MELD scores who are at high risk for early death.
Heuman DM; Abou-Assi SG; Habib A; Williams LM; Stravitz RT; Sanyal AJ; Fisher RA; Mihas AA
Hepatology; 2004 Oct; 40(4):802-10. PubMed ID: 15382176
[TBL] [Abstract][Full Text] [Related]
18. [Hyponatremia in Liver Cirrhosis].
Jang CM; Jung YK
Korean J Gastroenterol; 2018 Aug; 72(2):74-78. PubMed ID: 30145859
[TBL] [Abstract][Full Text] [Related]
19. Effects of satavaptan, a selective vasopressin V(2) receptor antagonist, on ascites and serum sodium in cirrhosis with hyponatremia: a randomized trial.
Ginès P; Wong F; Watson H; Milutinovic S; del Arbol LR; Olteanu D;
Hepatology; 2008 Jul; 48(1):204-13. PubMed ID: 18508290
[TBL] [Abstract][Full Text] [Related]
20. Hyponatremia in cirrhosis: Results of a patient population survey.
Angeli P; Wong F; Watson H; Ginès P;
Hepatology; 2006 Dec; 44(6):1535-42. PubMed ID: 17133458
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
